37533060|t|Presymptomatic and early pathological features of MAPT-associated frontotemporal lobar degeneration.
37533060|a|Early pathological features of frontotemporal lobar degeneration (FTLD) due to MAPT pathogenic variants (FTLD-MAPT) are understudied, since early-stage tissue is rarely available. Here, we report unique pathological data from three presymptomatic/early-stage MAPT variant carriers (FTLD Clinical Dementia Rating [FTLD-CDR] = 0-1). We examined neuronal degeneration semi-quantitatively and digitally quantified tau burden in 18 grey matter (9 cortical, 9 subcortical) and 13 white matter (9 cortical, 4 subcortical) regions. We compared presymptomatic/early-stage pathology to an intermediate/end-stage cohort (FTLD-CDR = 2-3) with the same variants (2 L315R, 10 P301L, 6 G272V), and developed a clinicopathological staging model for P301L and G272V variants. The 68-year-old presymptomatic L315R carrier (FTLD-CDR = 0) had limited tau burden morphologically similar to L315R end-stage carriers in middle frontal, antero-inferior temporal, amygdala, (para-)hippocampus and striatum, along with age-related Alzheimer's disease neuropathological change. The 59-year-old prodromal P301L carrier (FTLD-CDR = 0.5) had highest tau burden in anterior cingulate, anterior temporal, middle/superior frontal, and fronto-insular cortex, and amygdala. The 45-year-old early-stage G272V carrier (FTLD-CDR = 1) had highest tau burden in superior frontal and anterior cingulate cortex, subiculum and CA1. The severity and distribution of tau burden showed some regional variability between variants at presymptomatic/early-stage, while neuronal degeneration, mild-to-moderate, was similarly distributed in frontotemporal regions. Early-stage tau burden and neuronal degeneration were both less severe than in intermediate-/end-stage cases. In a subset of regions (10 GM, 8 WM) used for clinicopathological staging, clinical severity correlated strongly with neuronal degeneration (rho = 0.72, p < 0.001), less strongly with GM tau burden (rho = 0.57, p = 0.006), and did not with WM tau burden (p = 0.9). Clinicopathological staging showed variant-specific patterns of early tau pathology and progression across stages. These unique data demonstrate that tau pathology and neuronal degeneration are present already at the presymptomatic/early-stage of FTLD-MAPT, though less severely compared to intermediate/end-stage disease. Moreover, early pathological patterns, especially of tau burden, differ partly between specific MAPT variants.
37533060	50	54	MAPT	Gene	4137
37533060	66	99	frontotemporal lobar degeneration	Disease	MESH:D057174
37533060	132	165	frontotemporal lobar degeneration	Disease	MESH:D057174
37533060	167	171	FTLD	Disease	MESH:D057174
37533060	180	184	MAPT	Gene	4137
37533060	206	215	FTLD-MAPT	Disease	MESH:D057174
37533060	360	364	MAPT	Gene	4137
37533060	383	405	FTLD Clinical Dementia	Disease	MESH:D057174
37533060	414	418	FTLD	Disease	MESH:D057174
37533060	444	465	neuronal degeneration	Disease	MESH:D009410
37533060	511	514	tau	Gene	4137
37533060	711	715	FTLD	Disease	MESH:D057174
37533060	753	758	L315R	ProteinMutation	tmVar:p|SUB|L|315|R;HGVS:p.L315R;VariantGroup:2;CorrespondingGene:4137;RS#:63749855(Expired);CorrespondingSpecies:9606;CA#:225469
37533060	763	768	P301L	ProteinMutation	tmVar:p|SUB|P|301|L;HGVS:p.P301L;VariantGroup:0;CorrespondingGene:4137;RS#:63751273;CorrespondingSpecies:9606;CA#:225444
37533060	772	777	G272V	ProteinMutation	tmVar:p|SUB|G|272|V;HGVS:p.G272V;VariantGroup:1;CorrespondingGene:4137;RS#:63750376;CorrespondingSpecies:9606;CA#:225421
37533060	834	839	P301L	ProteinMutation	tmVar:p|SUB|P|301|L;HGVS:p.P301L;VariantGroup:0;CorrespondingGene:4137;RS#:63751273;CorrespondingSpecies:9606;CA#:225444
37533060	844	849	G272V	ProteinMutation	tmVar:p|SUB|G|272|V;HGVS:p.G272V;VariantGroup:1;CorrespondingGene:4137;RS#:63750376;CorrespondingSpecies:9606;CA#:225421
37533060	891	896	L315R	ProteinMutation	tmVar:p|SUB|L|315|R;HGVS:p.L315R;VariantGroup:2;CorrespondingGene:4137;RS#:63749855(Expired);CorrespondingSpecies:9606;CA#:225469
37533060	906	910	FTLD	Disease	MESH:D057174
37533060	932	935	tau	Gene	4137
37533060	970	975	L315R	ProteinMutation	tmVar:p|SUB|L|315|R;HGVS:p.L315R;VariantGroup:2;CorrespondingGene:4137;RS#:63749855(Expired);CorrespondingSpecies:9606;CA#:225469
37533060	1106	1150	Alzheimer's disease neuropathological change	Disease	MESH:D000544
37533060	1178	1183	P301L	ProteinMutation	tmVar:p|SUB|P|301|L;HGVS:p.P301L;VariantGroup:0;CorrespondingGene:4137;RS#:63751273;CorrespondingSpecies:9606;CA#:225444
37533060	1193	1197	FTLD	Disease	MESH:D057174
37533060	1221	1224	tau	Gene	4137
37533060	1368	1373	G272V	ProteinMutation	tmVar:p|SUB|G|272|V;HGVS:p.G272V;VariantGroup:1;CorrespondingGene:4137;RS#:63750376;CorrespondingSpecies:9606;CA#:225421
37533060	1383	1387	FTLD	Disease	MESH:D057174
37533060	1409	1412	tau	Gene	4137
37533060	1523	1526	tau	Gene	4137
37533060	1621	1642	neuronal degeneration	Disease	MESH:D009410
37533060	1727	1730	tau	Gene	4137
37533060	1742	1763	neuronal degeneration	Disease	MESH:D009410
37533060	1943	1964	neuronal degeneration	Disease	MESH:D009410
37533060	2012	2015	tau	Gene	4137
37533060	2068	2071	tau	Gene	4137
37533060	2160	2163	tau	Gene	4137
37533060	2240	2243	tau	Gene	4137
37533060	2258	2279	neuronal degeneration	Disease	MESH:D009410
37533060	2337	2346	FTLD-MAPT	Disease	MESH:D057174
37533060	2466	2469	tau	Gene	4137
37533060	2509	2513	MAPT	Gene	4137
37533060	Association	MESH:D057174	RS#:63751273;HGVS:p.P301L;CorrespondingGene:4137
37533060	Association	MESH:D057174	RS#:63750376;HGVS:p.G272V;CorrespondingGene:4137
37533060	Association	MESH:D000544	RS#:63749855(Expired);HGVS:p.L315R;CorrespondingGene:4137
37533060	Association	MESH:D057174	RS#:63749855(Expired);HGVS:p.L315R;CorrespondingGene:4137
37533060	Association	MESH:D057174	4137
37533060	Association	MESH:D000544	4137

